Overview

[KJ-INT-002] BE Study

Status:
Unknown status
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
Assess the Safety and the Pharmacokinetic Characteristics of INT-2150 after Oral Administration to Healthy Adult Male Subjects
Phase:
Phase 1
Details
Lead Sponsor:
Kukje Pharma
Treatments:
Irsogladine
Maleic acid
Nizatidine